Increasing Primary Care Utilization of Medication-Assisted Treatment (MAT) for Opioid Use Disorder

References

1. 1.↵
   Wide-ranging online data for epidemiologic research (WONDER). National Center for Health Statistics; 2021. Accessed 15 August, 2022. http://wonder.cdc.gov.
2. 2.↵
   1. Mattson CL,
   2. Tanz LJ,
   3. Quinn K,
   4. et al

   . Trends and geographic patterns in drug and synthetic opioid overdose deaths—United States, 2013–2019. MMWR 2021;70:202–7.

   OpenUrlPubMed
3. 3.↵
   US Department of Health and Human Services (HHS), Office of the Surgeon General. Facing addiction in America: the Surgeon General's spotlight on opioids. Department of Health and Human Services; 2018. Accessed 29 September 2021. https://www.ncbi.nlm.nih.gov/books/NBK538436/pdf/Bookshelf_NBK538436.pdf.
4. 4.↵
   1. Tong S,
   2. Crothers G,
   3. Bazemore A,
   4. et al

   . Addressing the opioid epidemic with the primary care workforce. Poster presentation at the 44th Annual Meeting of the North American Primary Care Research Group, November 12–16, 2016, Colorado Springs, CO.
5. 5.↵
   1. Rosenblatt RA,
   2. Andrilla CH,
   3. Catlin M,
   4. Larson EH

   . Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med 2015;13:23–6.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Collins C,
   2. Hewson DL,
   3. Munger R,
   4. Wade T

   . Evolving models of behavioral health integration in primary care. Milbank Memorial Fund; 2010.
7. 7.↵
   1. Starfield B,
   2. Cassady C,
   3. Nanda J,
   4. et al

   . Consumer experiences and provider perceptions of the quality of primary care: implications for managed care. J Fam Pract 1998;46:216–26.

   OpenUrlPubMedWeb of Science
8. 8.↵
   1. Hill R

   . Medication-assisted treatment should be part of every family physician's practice. Ann Fam Med 2017;15:310–2.

   OpenUrlFREE Full Text
9. 9.↵
   The science of drug use and addiction: the basics. National Institute on Drug Abuse; 2020. Accessed 29 September 2021. https://www.drugabuse.gov/publications/media-guide/science-drug-use-addiction-basics.
10. 10.↵
    1. Bodenheimer T,
    2. Sinsky C

    . From triple to quadruple aim: care of the patient requires care of the provider. Ann Fam Med 2014;12:573–6.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    Medications for opioid use disorder: for healthcare and addiction professionals, policymakers, patients, and families. Substance Abuse and Mental Health Services Administration; 2021. Accessed 15 August 2022. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/PEP21-02-01-002.pdf.
12. 12.↵
    1. Dowell D,
    2. Haegerich TM,
    3. Chou R

    . CDC guidelines for prescribing opioids for chronic pain—United States, 2016. MMWR Recomm Rep 2016;65:1–49.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. McLellan AT,
    2. Lewis DC,
    3. O'Brien CP,
    4. Kleber HD

    . Drug dependence, a chronic medical illness: Implications for treatment, insurance, and outcomes evaluation. JAMA 2000;284:1689–95.

    OpenUrlCrossRefPubMedWeb of Science
14. 14.↵
    1. Levounis P,
    2. Arnaout B,
    3. Marienfeld C

    1. Nunes EV

    . Motivational interviewing in addiction treatment. In Levounis P, Arnaout B, Marienfeld C eds. Motivational interviewing for clinical practice. American Psychiatric Publishing; 2017:3–14.
15. 15.↵
    1. Miller WR,
    2. Rollnick S

    . Motivational interviewing: helping people change. Guilford Press; 2013.
16. 16.↵
    1. Ball SA,
    2. Martino S,
    3. Nich C,
    4. et al

    . Site matters: multisite randomized trial of motivational enhancement therapy in community drug abuse clinics. J Consult Clin Psychol 2007;75:556–567.

    OpenUrlPubMed
17. 17.↵
    1. Bein TH,
    2. Miller WR,
    3. Boroughs JM

    . Motivational interviewing with alcohol outpatients. Behav Cogn Psychother 1993;21:347–56.

    OpenUrlCrossRef
18. 18.↵
    1. Carroll KM,
    2. Ball SA,
    3. Nich C,
    4. et al

    . Motivational interviewing to improve treatment engagement and outcome in individuals seeking treatment for substance abuse: a multisite effectiveness study. Drug Alcohol Depend 2006;81:301–12.

    OpenUrlCrossRefPubMedWeb of Science
19. 19.↵
    1. Marlatt GA,
    2. Baer JS,
    3. Kivlahan DR,
    4. et al

    . Screening and brief intervention for high-risk college student drinkers: Results from a 2-year follow-up assessment. J Consult Clin Psychol 1998;66:604–15.

    OpenUrlCrossRefPubMedWeb of Science
20. 20.↵
    1. Miller WR,
    2. Benefield RG,
    3. Tonigan JS

    . Enhancing motivation for change in problem drinking: A controlled comparison of two therapist styles. J Consult Clin Psychol 1993;61:455–61.

    OpenUrlCrossRefPubMedWeb of Science
21. 21.↵
    1. Bohnert AS,
    2. Bonar EE,
    3. Cunningham R,
    4. et al

    . A pilot randomized clinical trial of an intervention to reduce overdose risk behaviors among emergency department patients at risk for prescription opioid overdose. Drug Alcohol Depend 2016;163:40–7.

    OpenUrl
22. 22.↵
    1. Chang YP,
    2. Compton P,
    3. Almeter P,
    4. Fox CH

    . The effect of motivational interviewing on prescription opioid adherence among older adults with chronic pain. Perspect Psychiatr Care 2015;51:211–9.

    OpenUrl
23. 23.↵
    1. Navidian A,
    2. Kermansaravi F,
    3. Tabas EE,
    4. Saeedinezhad F

    . Efficacy of group motivational interviewing in the degree of drug craving in the addicts under the methadone maintenance treatment (MMT) in the South East of Iran. Arch Psychiatr Nurs 2016;30:144–9.

    OpenUrl
24. 24.↵
    1. Levounis P,
    2. Arnaout B,
    3. Marienfeld C

    1. Kim SA,
    2. Kalira V

    . Motivational interviewing and pharmacotherapy. In: Levounis P, Arnaout B, Marienfeld C eds. Motivational interviewing for clinical practice. American Psychiatric Publishing; 2017:131–50.
25. 25.↵
    1. Bandura A

    . Social cognitive theory: an agentic perspective. Annu Rev Psychol 2001;52:1–26.

    OpenUrlCrossRefPubMedWeb of Science
26. 26.↵
    1. Stajkovic AD,
    2. Luthans F

    . Social cognitive theory and self-efficacy: going beyond traditional motivational and behavioral approaches. Organizational dynamics 1998;26:62–74.

    OpenUrlCrossRef
27. 27.↵
    1. McLeod PJ,
    2. Steinert Y,
    3. Snell L

    . Use of retrospective pre/post assessments in faculty development. Med Educ 2008;42:543.

    OpenUrlPubMed
28. 28.↵
    1. Bilodeau A,
    2. Dumont S,
    3. Hagan L,
    4. et al

    . Interprofessional education at Laval University: building an integrated curriculum for patient-centered practice. J Interprof Care 2010;24:524–35.

    OpenUrlPubMed
29. 29.↵
    1. Rosenbaum ME,
    2. Rowat JA,
    3. Ferguson KJ,
    4. et al

    . Developing future faculty: a program targeting internal medicine fellows' teaching skills. J Grad Med Educ 2011;3:302–8.

    OpenUrlPubMed
30. 30.↵
    1. Read KB,
    2. Larson C,
    3. Gillespie C,
    4. et al

    . A two-tiered curriculum to improve data management practices for researchers. PloS One 2019;14:e0215509.

    OpenUrl
31. 31.↵
    1. Hafler JP

    1. Svinicki MD,
    2. Wilkerson L

    . Faculty development for workplace instructors. In: Hafler JP ed. Extraordinary learning in the workplace. Springer; 2011:131–64.
32. 32.↵
    SPSS Statistics for Windows, v.26.0. IBM Corp; 2019.
33. 33.↵
    1. Arbuckle JL

    . Amos, v.26.0. IBM Corp; 2019.
34. 34.↵
    1. Padala AP,
    2. Wilson KB,
    3. Das A

    . The opioid epidemic and the COVID-19 pandemic: similarities in biology and differences in response to 2 public health crises. Prim Care Companion CNS Disord 2022;24:21com03149.

    OpenUrl